US biotech companies say gene patents not at odds with patient access
This article was originally published in RAJ Devices
Executive Summary
US biotech companies are worried that recommendations of a government task force on gene patenting and licensing, if implemented, could restrict the ability to obtain, or undermine the enforceability of, patents and exclusive licences with respect to genetic tests, according to the Biotechnology Industry Organization1,2.